Diffuse large B-cell lymphoma presenting as a scalp tumor with skull destruction and neurological symptoms: a case report - Top-Institutions - MDSpire

Diffuse large B-cell lymphoma presenting as a scalp tumor with skull destruction and neurological symptoms: a case report

  • By

  • Ayaka Yasuda

  • Natsuko Saito-Sasaki

  • Hirofumi Kawamoto

  • Yu Sawada

  • May 29, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Hematology-Oncology
    • Oncology

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Hematology-Oncology

  • #3

    Memorial Sloan Kettering Cancer Centre
    Memorial Sloan Kettering Cancer Centre

    New York, New York

    Key Differentiators

    • Hematology-Oncology

  • #4

    Temple University Hospital
    Temple University Hospital

    Philadelphia, Pennsylvania

    Key Differentiators

    • Hematology-Oncology

  • #5

    Nordic Lymphoma Group
    Nordic Lymphoma Group

    N/A, N/A

    Key Differentiators

    • Hematology-Oncology

Original Source(s)

Diffuse large B-cell lymphoma presenting as a scalp tumor with skull destruction and neurological symptoms: a case report

  • by Ayaka Yasuda, Natsuko Saito-Sasaki, Hirofumi Kawamoto, Yu Sawada

  • May 29, 2026

Related Content

Why We Made a Mobile Digital Pathology Lab

Todd R. Minnigh and his team created ScanVan to address a problem with rare cancer diagnosis that had a particularly personal significance

Could One Test Replace Multiple Leukemia Assays?

Researchers assess whether long-read transcriptome sequencing can streamline B-ALL diagnostics

  • May 29, 2026

  • 3 min
Preclinical Study in Mice Addresses a Question: Should RAS Inhibitors Be Given Preemptively?

With recent data that RAS inhibition can improve survival in metastatic pancreatic cancer, the optimization of these agents has become a research priority. Minh Than, MD, PhD, a clinical and research ...